Results 71 to 80 of about 677,625 (318)

Placebos in the clinic [PDF]

Journal of the Royal Society of Medicine, 2013
In 1954, it was reported in The Lancet that ‘Those who have qualms of conscience about prescribing pharmacologically useless medicines tend to use semi-placebos, such as vitamins, in the vague hope that these may do some good’.1 Except that the reasons for writing the prescriptions may not be quite so innocent, the same holds true today, decades into ...
openaire   +2 more sources

Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. [PDF]

, 2008
BACKGROUND: Malaria and anaemia are the leading causes of morbidity and mortality in children in sub-Saharan Africa. We have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on ...
Kweku Margaret, Liu Dongmei, Adjuik, Martin, Daniel Chandramohan, Greenwood Brian, Margaret Kweku, Binka Fred, Fred Binka, Binka, Fred, Chandramohan, Daniel, Mahmood Seidu, Liu, Dongmei, Dongmei Liu, Seidu, Mahmood, Martin Adjuik, Greenwood, Brian, Brian Greenwood, Kweku, Margaret, Seidu Mahmood, Adjuik Martin, Chandramohan Daniel   +20 more
core   +1 more source

Translational Considerations for Injectable Biomaterials and Bioscaffolds to Repair and Regenerate Brain Tissue

Advanced Healthcare Materials, EarlyView.
The repair and regeneration of brain tissue faces both biological and technical challenges. Injectable bioscaffolds offer new opportunities to stimulate tissue regrowth in the brain by recruiting neural stem cells. Here, the translational issues are reviewed that need to be address to advance this promising new therapeutic approach from the bench to ...
Michel Modo, Alena Kisel
wiley   +1 more source

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Hepatic Medicine: Evidence and Research, 2020
Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St.
Zhdanov K, Isakov V, Burnevich E, Kizhlo S, Bakulin I, Pokrovsky V, Liang L, Hwang P, Talwani R, Haber BA, Robertson MN   +10 more
doaj  

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis [PDF]

Journal of Vector Borne Diseases, 2008
Background & objectives: Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment ...
M.A. Nilforoushzadeh, F. Jaffary, N. Ansari, A.H. Siadat, Z. Nilforoushan, A. Firouz   +5 more
doaj  

Who responds to a placebo? Factors associated with response to placebo during a double-blind randomised controlled trial [PDF]

, 2020
INTRODUCTION: The placebo effect, a desirable outcome resulting from a person’s expected and/or learned response to a treatment or situation, may significantly influence the interpretation of double-blind, randomised controlled trials (RCT). High placebo
Hurst, P., Coleman, D., Saunders, S.
core  

Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease

Advanced Science, EarlyView.
ABSTRACT Accumulating evidence suggests that the intestinal microbiota participates in the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD) through microbiota‐host interaction. However, the beneficial role of commensal mycobiota in MASLD progression remains poorly understood.
Shuping Qiao, Shuangya Fan, Juan Xu, Zhen Xu, Chen Peng, Junxing Qu, Ziqian Bing, Shizhen Zhou, Sunan Shen, Guifang Xu, Yue Zhao, Tingting Wang   +11 more
wiley   +1 more source

Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)

Health Technology Assessment
Background Variation in the way information about potential trial intervention benefits and harms is conveyed within patient information leaflets can cause avoidable information-induced (‘nocebo’) harm, research waste, and may be unethical. Objectives To
Jeremy Howick, Martina Svobodova, Shaun Treweek, Katie Gillies, Adrian Edwards, Peter Bower, Jennifer Bostock, Nina Jacob, Kerenza Hood   +8 more
doaj   +1 more source

Randomisation in a clinical trial: is it feasible in the Ebola crisis? If it is, then which method is suitable?

Southern African Journal of Infectious Diseases, 2016
Randomisation is an integral component of any sensible clinical trial. Randomisation is the only way we can be sure that the patients have been allocated into the treatment arms with as minimum bias as possible, and that the treatment arms are similar ...
Jesca M. Batidzirai
doaj   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

Advanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak, David Okoh, William Scotton, Shanika Samarasekera, Vikram Patil, Suresh Renukappa, Andrew Macduff, Subashini Suresh, Rajeev Krishnadas, Tonny Veenith   +9 more
wiley   +1 more source